Efficacy and toxicity of fluorouracil, doxorubicin, and cisplatin/nedaplatin treatment as neoadjuvant chemotherapy for advanced esophageal carcinoma

Scandinavian Journal of Gastroenterology

Volumn 40, Issue 8, 2005, Pages 886-892

  Kosugi, Shin Ichi ^a   Kanda, Tatsuo ^a   Nakagawa, Satoru ^a   Ohashi, Manabu ^a   Nishimaki, Tadashi ^b   Hatakeyama, Katsuyoshi ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b UNIVERSITY OF THE RYUKYUS   (Japan)

Author keywords

Efficacy; Esophageal carcinoma; FAP N; Neoadjuvant chemotherapy; Toxicity

Indexed keywords

CISPLATIN; DOXORUBICIN; FLUOROURACIL; NEDAPLATIN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; ESOPHAGUS CARCINOMA; ESOPHAGUS RESECTION; HUMAN; INFECTION; LARYNGITIS; LEUKOPENIA; MALE; MUCOSA INFLAMMATION; NAUSEA; PRIORITY JOURNAL; STOMATITIS; SURVIVAL RATE; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DISEASE-FREE SURVIVAL; DOXORUBICIN; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 23644451933     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365520510015601     Document Type: Article

References (19)

1. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003;349:2241-52.
2. Ancona E, Ruol A, Castoro C, Chiarion-Sileni V, Merigliano S, Santi S, et al. First-line chemotherapy improves the resection rate and long-term survival of locally advanced (T4, any N, M0) squamous cell carcinoma of the thoracic esophagus. Ann Surg 1997;226:714-24.
3. Nishimaki T, Suzuki T, Suzuki S, Kuwabara S, Hatakeyama K. Outcomes of extended radical esophagectomy for thoracic esophageal cancer. J Am Coll Surg 1998;186:306-12.
4. Nishimaki T, Suzuki T, Tanaka Y, Aizawa K, Hatakeyama K, Muto T. Intramural metastases from thoracic esophageal cancer: local indicators of advanced disease. World J Surg 1996;20:32-7.
5. Lordick F, Stein HJ, Peschel C, Siewert JR. Neoadjuvant therapy for oesophagogastric cancer. Br J Surg 2004;91: 540-51.
6. Yasuda T, Kabuto T, Ishiguro S, Nakano H, Nakamori S, Ohigashi H, et al. Preoperative neoadjuvant chemotherapy with a combination of 5-fluorouracil, adriamycin and cisplatin (FAP) for advanced esophageal cancer invading trachea or main bronchus. Gan To Kagaku Ryoho (Jpn J Cancer Chemother) 1995;22:1538-41.
7. Kabuto T, Yasuda T, Kobayashi T, Kodama K, Higasiyama M, Yokouchi H, et al. Design to improve the therapeutic results in A3 esophageal cancer: combined resection and neoadjuvant chemotherapy. Nippon Kyobu Geka Gakkai Zasshi 1997;45:348-50.
8. Sobin LH, Wittekind Ch. TNM classification of malignant tumours, 6th ed. New York: Wiley-Liss; 2002.
9. Japanese Society for Esophageal Disease. Guidelines for the clinical and pathological studies on carcinoma of the esophagus, 9th ed. Tokyo: Kanehara; 1999.
10. Urschel JD, Vasan H, Blewett CJ. A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2002;183:274-9.
11. Kelsen DP, Ginsberg R, Pajak TF, Sheahan DG, Gunderson L, Mortimer J, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998;339:1979-84.
12. Medical Research Council Oesophageal Working Party. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomized controlled trial. Lancet 2002;359:1727-33.
13. Kato H, Fukuchi M, Manda R, Nakajima M, Miyazaki T, Sohda M, et al. Efficacy and toxicity of nedaplatin and 5-FU with radiation treatment for advanced esophageal carcinomas. Anticancer Res 2003;23:3493-8.
14. Roth JA, Pass HI, Flanagan MM, Graeber GM, Rosenberg JC, Steinberg S. Randomized clinical trials of preoperative and postoperative adjuvant chemotherapy with cisplatin, vindesine, and bleomycin for carcinoma of the esophagus. J Thorac Cardiovasc Surg 1988;96:242-8.
15. Schlag PM. Randomized trial of preoperative chemotherapy for squamous cell carcinoma of the esophagus. Arch Surg 1992;127:1446-50.
16. Law S, Fok M, Chow S, Chu KM, Wong J. Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial. J Thorac Cardiovasc Surg 1997;114:203-4.
17. Ancona E, Ruol A, Santi S, Merigliano S, Sileni VC, Koussis H, et al. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long-term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer 2001;91:2165-74.
18. Kelsen D, Pajak T, Ginsberg R. Treatment of esophageal cancer [letter]. N Engl J Med 1999;340:1686-7.
19. Baba M, Natsugoe S, Shimada M, Nakano S, Kusano C, Fukumoto T, et al. Prospective evaluation of preoperative chemotherapy in resectable squamous cell carcinoma of the thoracic esophagus. Dis Esophagus 2000;13:136-41.